Light Adjustable Lens logo

Join Us at AAO
in San Francisco

November 4-5, 2023
The Moscone Center
Booth 229

In-Booth Speakers

Join us at AAO, Booth 229, to hear from our lineup of insightful speakers how the RxSight Light Adjustable Lens® (LAL®) has transformed their work and how they have integrated this groundbreaking technology into their practices. They will also share valuable tips for starting or enhancing your own LAL program. Don’t get left in the dark, view the full schedule below.

Saturday, November 4

10:00 am
LAL Use Across Diverse Patient Profiles
Eva Kim, MD
Add to Calendar
10:30 am
Initial Clinical Experience with the LAL+
Stephen Slade, MD
Add to Calendar
11:00 am
0 to 60: Your LAL Practice at the Speed of Light
Gary Foster, MD
Add to Calendar
12:00 pm
Growing the Premium Channel with the LAL
Alan McCarty, MD
Add to Calendar
1:00 pm
Case Studies: Role of DOF for Optimizing Range of Vision
John Vukich, MD
Add to Calendar
2:00 pm
Optimizing LAL Workflow in a Co‑Management Setting
Priya Mathews, MD
Add to Calendar
3:00 pm
Using the Light Adjustable Lens in Glaucoma Patients
George Tanaka, MD
Add to Calendar
4:00 pm
How I Regained Confidence with the LAL
Bennett Walton, MD
Add to Calendar

Sunday, November 5

10:00 am
Tips for LAL Success in Different Office Types
Michael Summerfield, MD
Add to Calendar
11:00 am
LAL in Focus: Profiling a Range of Patients and Their Outcomes
Rex Hamilton, MD
Add to Calendar
12:00 pm
Understanding Monovision Tolerance in LAL Patients
Paul Phillips, MD
Add to Calendar
1:00 pm
Increasing LAL Adoption in My Office-Based Surgical Practice
John Josephson, MD
Add to Calendar
2:00 pm
Case Studies of Blended Vision in LAL Patients
Brett Mueller, DO
Add to Calendar
3:00 pm
IOL Exchange with the LAL in Unhappy ATIOL Patients
Nicole Fram, MD
Add to Calendar
4:00 pm
Building a Premium Practice One Satisfied Patient at a Time
Sharon Richens, MD
Add to Calendar
This communication is not affiliated with the official program of AAO, its 2023 Annual Meeting, or any of its subsidiaries.

©2023 RxSIGHT. All Rights Reserved. COM-1079 Rev. A

LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

The LAL provides optimized vision for patient satisfaction.2

LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

Since the LAL is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.

LAL patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The LAL offers LASIK-like accuracy in cataract surgery.2,3

92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).

Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.

The Light Adjustable Lens corrects down to 0.5 diopters of postoperative cylinder.

The Light Adjustable Lens corrects down to 0.5 diopters of astigmatism, which is the lowest level approved to be treated.

The ability to treat 0.50 D of postoperative cylinder makes the Light Adjustable Lens the only IOL in the United States approved to correct this level of vision-altering astigmatism. Astigmatism of as little as 0.50 D can reduce visual acuity by one line, and the impact on dynamic, functional visual acuity and low-contrast acuity is even greater.1